View Post

TAILORx High-Risk Group Analysis Adds to Oncotype DX Chemo-Prediction Data

In Clinical Trials by Barbara Jacoby

By: Staff Reporter From: In secondary analysis of data from the TAILORx trial, researchers have added new confirming evidence that patients with high risk scores from Genomic Health’s Oncotype DX appear to benefit significantly from added chemotherapy. Investigators led by the trial’s PI Joseph Sparano shared their findings in JAMA Oncology today and also presented the analysis at the …